Guggenheim initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $60 price target citing a positive view of its two highly optimized, best-in-class, longer-acting antibodies with validated targets. Although current biologics are highly efficacious with minimal safety risks, the firm believes Oruka’s drugs could deliver rapid, deep and sustained responses with an ideal maintenance profile across multiple chronic immunology and inflammation indications, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
- Oruka Therapeutics initiated with an Overweight at Barclays
- Oruka Therapeutics files to sell 39.43M shares of common stock for holders
- Promising Future for Oruka Therapeutics: Buy Rating Backed by ORKA-002’s Market Potential and Strategic Expansion
- Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis